Lixte Biotech Hlds (LIXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2014 | 12-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,069 | 2,599 | N/A | N/A | N/A |
| Receivables | N/A | 14 | N/A | N/A | N/A |
| Other current assets | 77 | 0 | 0 | 0 | 0 |
| TOTAL | $5,229 | $2,672 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $5,229 | $2,672 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 190 | 144 | 0 | 0 | 0 |
| Accrued Expenses | 11 | N/A | N/A | N/A | N/A |
| Other current liabilities | 16 | 94 | N/A | N/A | N/A |
| TOTAL | $217 | $238 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $217 | $238 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,354 | N/A | N/A | 45,576 | 41,583 |
| Common Shares | 1 | 1 | N/A | N/A | N/A |
| Retained earnings | -30,354 | -27,089 | N/A | N/A | N/A |
| TOTAL | $5,012 | $2,434 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $5,229 | $2,672 | $0 | $0 | $0 |